ÍøÆØÃÅ

Upperton has developed UpperNoseâ„¢, a nasal product development approach designed to streamline the development process for nasal dosage forms. UpperNoseâ„¢ aims to facilitate the development of molecules, ensuring a smooth transition from early-stage development to clinical trials.

The UpperNoseâ„¢ development process involves:

• Target product profile development: Defining the anticipated dose and frequency of dosing
• Pre-formulation and stability screening: Evaluating formulation stability and compatibility
• Selection of dosage form: Choosing the appropriate dosage form based on development needs
• Formulation and process development: Creating formulations and processes that support regulatory submissions and toxicology evaluations
• Clinical batch manufacture: Producing batches for clinical trials

Applications of UpperNoseâ„¢:

• Local delivery: Targeting nasal membranes for vaccines, antivirals, and prophylactics
• Systemic delivery: Absorbing into the bloodstream for rapid action while avoiding first-pass metabolism
• Direct delivery to the brain: Bypassing the blood-brain barrier to address neurodegenerative and psychological disorders

Benefits of UpperNoseâ„¢:

• Regulatory data: Provides data necessary for regulatory submissions
• Expert-driven approach: Led by a highly experienced team, UpperNoseâ„¢ addresses the unique needs of each molecule
• Device compatibility: Works with both customer-specific and commercially available nasal delivery devices
• Commercial success: Establishes a clear path to commercial success, helping clients reach milestones

We’re specialists in the use of pharmaceutical spray drying to improve the solubility and bioavailability of your formulation, helping to enhance the dissolution rate and stability.

Our early formulation platform, UpperSolv™, outlines a parallel integrated formulation and biopharmaceutical screening protocol that can rapidly compare a range of enabling formulation strategies that can be translated into clinical processes and products – helping to identify a successful formulation strategy.